Compare SBI & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBI | XGN |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.9M | 110.4M |
| IPO Year | N/A | 2014 |
| Metric | SBI | XGN |
|---|---|---|
| Price | $7.82 | $4.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 35.7K | ★ 372.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.40 | $2.59 |
| 52 Week High | $8.01 | $12.23 |
| Indicator | SBI | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 52.87 |
| Support Level | $7.79 | $4.11 |
| Resistance Level | $7.90 | $4.85 |
| Average True Range (ATR) | 0.07 | 0.38 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 54.55 | 38.57 |
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.